10x Genomics announced the creation of the Asia‑Pacific Spatial Translational Research Alliance (ASTRA), a partnership with the Garvan Institute of Medical Research in Australia and the University of Tokyo in Japan. The consortium will deploy 10x’s Xenium spatial platform to map immune‑cell interactions in 2,000 tumor samples representing ten major cancer types, creating the first comprehensive pan‑cancer atlas for the region.
The launch targets a region that carries a disproportionate cancer burden and has historically been under‑represented in global datasets. By democratizing access to high‑resolution spatial data, ASTRA aims to accelerate precision oncology research and provide a shared foundation for personalized medicine across diverse populations. The collaborative model—combining local expertise with 10x’s technology—positions the company as the leading spatial biology provider in the Asia‑Pacific market.
In its most recent quarterly report, 10x Genomics posted revenue of $149 million for Q3 2025, beating the consensus estimate of $142.4 million by $6.6 million (4.6%). Net loss narrowed to $27.5 million from $35.8 million a year earlier, while gross margin fell to 67% from 70% due to a shift toward lower‑margin instrument sales and higher inventory write‑downs. The company guided Q4 revenue to $154–$158 million, a 6% decline from the prior year but a 5% sequential increase at the midpoint, reflecting confidence in sustained demand for its single‑cell and spatial products.
CEO Serge Saxonov highlighted the company’s “solid third quarter” and noted that the firm’s “strong balance sheet and disciplined execution” give it confidence to navigate the current environment. Dr. Ankur Sharma of the Garvan Institute described ASTRA as “a new model for scientific collaboration—agile, distributed, and deeply connected to the healthcare needs of the Asia‑Pacific region.” Dr. Yutaka Suzuki of the University of Tokyo added that the alliance “will capture the cellular complexity of cancer in our populations and build a shared foundation for truly personalized medicine.”
The Q3 earnings beat generated a positive market reaction, with analysts citing robust demand in core segments and a stronger-than‑expected Q4 guidance as key drivers. The revenue beat of $6.6 million and the improved loss per share of $0.22 versus the consensus $0.28 underscored the company’s ability to manage costs while expanding its spatial biology portfolio.
ASTRA’s launch, coupled with 10x Genomics’ solid financial performance, signals a strategic push to deepen its footprint in a high‑growth region while maintaining disciplined cost management. The company’s ability to narrow its net loss and guide for sequential revenue growth suggests resilience, but the margin compression highlights the need for continued focus on pricing power and operational efficiency as it scales its spatial platform.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.